NasdaqGS:INCYBiotechs
A Look At Incyte (INCY) Valuation After Positive frontMIND Phase 3 Lymphoma Trial Results
Why the frontMIND trial update matters for Incyte (INCY)
Incyte (INCY) is in focus after reporting that its pivotal Phase 3 frontMIND trial in previously untreated high-risk diffuse large B-cell lymphoma showed a significant clinical benefit from adding tafasitamab and lenalidomide to standard R-CHOP therapy.
The company highlighted a 25% reduction in the risk of disease progression or death with the combination regimen versus R-CHOP alone, supporting planned global regulatory submissions and...